Navigation Links
UV light improving chances of fighting cancer
Date:10/29/2007

Scientists at Newcastle University have developed a cancer fighting technology which uses UV light to activate antibodies which very specifically attack tumours.

Therapeutic antibodies have long been recognised as having excellent potential but getting them to efficiently target tumour cells has proved to be very difficult.

Now, Professor Colin Self and Dr Stephen Thompson from Newcastle University have developed a procedure to cloak antibodies which can then be activated by UV-A light and so can be targeted to a specific area of the body just by shining a probe at the relevant part.

This procedure maximizes the destruction of the tumour while minimising damage to healthy tissue.

Professor Self says, I would describe this development as the equivalent of ultra-specific magic bullets. This could mean that a patient coming in for treatment of bladder cancer would receive an injection of the cloaked antibodies. She would sit in the waiting room for an hour and then come back in for treatment by light. Just a few minutes of the light therapy directed at the region of the tumour would activate the T-cells causing her bodys own immune system to attack the tumour.

The details are contained in two papers* published online today in the journal ChemMedChem.

The Newcastle University researchers demonstrate in the first paper the procedure of coating the surface of a protein, such as an antibody, with an organic oil which is photocleavable, a process called cloaking. This prevents the antibody reacting within the body unless it is illuminated.

When UV-A light is shone onto the cloaked antibody it is activated. The activated antibody binds to T-cells, the bodys own defence system, triggering the T-cells to target the surrounding tissue.

In the second paper, they demonstrate that when the cloaked antibodies are activated by light near a tumour, the tumour is killed. This work means that antibodies can be targeted to kill cancer tumours with much greater specificity giving fewer side effects.

These cloaked antibodies can be used alone, or in conjunction with the many antibodies already produced against a wide variety of cancers as bispecific complexes. These complexes are formed from two antibodies, one antibody binds to a tumour marker, the other with a T-cell. The T-cell binding end remains inactive until re-activated by light. This means when the bispecific antibody binds to healthy tissues away from light, it cannot activate T-cells, resulting in far fewer side effects.

Professor Self says, This opens up so many possible applications for example, for patients who are undergoing surgery for prostate cancer. After the surgeon has removed the bulk of a tumour, the patient could then be injected with bispecific antibodies and a light shone at the affected area which would target the patients own immune system to the tumour site.

This is therefore a very specific treatment and while our work indicates that sunlight doesnt activate these antibodies, patients may have to be advised to avoid direct sunlight for a short period after treatment.


'/>"/>

Contact: Karen Bidewell
press.office@ncl.ac.uk
01-912-226-972
Newcastle University
Source:Eurekalert

Related biology news :

1. Researchers discover way to make cells in the eye sensitive to light
2. Recent breakthroughs in common adult leukemia highlighted in New England Journal of Medicine
3. Bacteria collection sheds light on urinary tract infections
4. Sea skate experiment sheds light on human cell transport
5. X-Ray Beams And Fruit Fly Flight Simulator Aid Scientists View Of Muscle Power
6. McGill researchers shed light on formation of carcinogen in food
7. Scientists discover how plants disarm the toxic effects of excessive sunlight
8. Light therapy may combat fungal infections, new evidence suggests
9. Medical molecules designed to respond to visible light that can penetrate tissue
10. Genetic defects give the immune system the green light to attack the pancreas
11. Researchers find gene that may be at root of potato blight
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2016)... , Dec. 14, 2016 "Increase in mobile ... market" The mobile biometrics market is expected to grow ... billion by 2022, at a CAGR of 29.3% between ... such as the growing demand for smart devices, government ... "Software component is expected to grow at ...
(Date:12/7/2016)... , December 7, 2016 According to a new market ... Software Tool (Facial Expression, Voice Recognition), Service, Application Area, End User, And Region ... to grow from USD 6.72 Billion in 2016 to USD 36.07 Billion by ... Continue Reading ... MarketsandMarkets ...
(Date:12/6/2016)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) (the "Company") ... million principal amount of its 1.414% senior unsecured notes due ... unsecured notes due 2026. The closing of ... to the satisfaction of customary closing conditions.  The notes will ... The Company intends to use the net proceeds from ...
Breaking Biology News(10 mins):
(Date:1/17/2017)... Cumberland Foreside, Maine (PRWEB) , ... January 17, ... ... to announce the addition of Rheumatoid Factor (RF) to its VALIDATE® SP2 calibration ... and Rheumatoid Factor in a human serum base. Each VALIDATE® SP2 kit is ...
(Date:1/17/2017)... DIEGO , Jan. 17, 2017  An ... School of Medicine and St. Boniface Hospital Albrechtsen ... for peripheral neuropathy, an unmet health need affecting ... the Journal of Clinical Investigation, their results identify ... that prevent and reverse neuronal injury in animal ...
(Date:1/17/2017)... 2017   Pulmatrix, Inc . (NASDAQ: ... inhaled therapies to address serious pulmonary diseases, today announced ... the lungs of CF patients, PUR1900, has been designated ... U.S. Food & Drug Administration. Under ... the development of novel drugs against important pathogens, Pulmatrix ...
(Date:1/17/2017)...  Only nine percent of U.S. consumers believe pharmaceutical ... 16 percent believe health insurance companies do, according to ... of U.S. adults believe health care providers (such as ... hospitals (23%). "We are in the midst ... , vice president of reputation management and public affairs ...
Breaking Biology Technology: